Halozyme Therapeutics Stock Forecast for 2023 - 2025 - 2030
Updated on 04/24/2024
Halozyme Therapeutics Stock Forecast and Price Target
According to three esteemed experts, the average price target for Halozyme Therapeutics to reach this year is $48.50, with a potential upside of approximately 23.98%. This prediction is based on a high estimate of $72.00 and a low estimate of $39.00. If interested in HALO stock, you may also want to consider its competitors.
23.98% Upside
Halozyme Therapeutics Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Halozyme Therapeutics's Price has fallen from $13.59 to $0.00 – a 100.00% decrease. In the next year, analysts are expecting an increase in Fair Value, predicting it will reach $56.58 – an increase of 100.00%. The Halozyme Therapeutics forecast is for Fair Value to reach $154.08 or grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| GOOGL Stock Forecast | Alphabet | Outperform |
14
|
$159.13 | Buy/Sell | $163.84 | 6.83% |
| AMZN Stock Forecast | Amazon.com Inc | Buy |
13
|
$176.59 | Buy/Sell | $204.68 | 21.18% |
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$732.20 | Buy/Sell | $636.99 | 14.38% |
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$167.80 | Buy/Sell | $178.42 | 12.63% |
| NOVN Stock Forecast | Novartis | Hold |
10
|
CHF89.12 | Buy/Sell | CHF105.00 | 20.68% |
Halozyme Therapeutics Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Halozyme Therapeutics's Revenue has increased by 209.90%, going from $267.59M to $829.25M. In the next year, analysts are expecting an increase in Revenue, predicting it will reach $1.12B – an increase of 35.33%. The Halozyme Therapeutics forecast is for Revenue to reach $2.02B or grow by 143.05%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| PFE Stock Forecast | Pfizer | Outperform |
2
|
$26.27 | Buy/Sell | $32.87 | 16.10% |
| BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$48.86 | Buy/Sell | $58.15 | 12.57% |
| CVS Stock Forecast | CVS Health | Outperform |
12
|
$67.77 | Buy/Sell | $89.54 | 29.56% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| GSK Stock Forecast | GSK | Outperform |
12
|
£16.36 | Buy/Sell | £17.30 | 19.19% |
| SUNPHARMA Stock Forecast | Sun Pharmaceutical Industries | Outperform |
8
|
Rp1.49k | Buy/Sell | Rp1.52k | 6.68% |
| WST Stock Forecast | West Pharmaceutical Services | Outperform |
18
|
$385.73 | Buy/Sell | $380.80 | -1.49% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| RCI.B Stock Forecast | Rogers Communications | Outperform |
16
|
C$52.30 | Buy/Sell | C$73.56 | 41.49% |
| TEVA Stock Forecast | Teva Pharmaceutical Industries | Outperform |
12
|
$13.01 | Buy/Sell | $11.59 | 22.98% |
| VTRS Stock Forecast | Viatris Inc | Hold |
8
|
$11.55 | Buy/Sell | $11.73 | 3.90% |
Halozyme Therapeutics EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Halozyme Therapeutics's EBITDA has grown, increasing from $145.84M to $416.69M – a growth of 185.72%. The next year looks promising for Halozyme Therapeutics, with analysts predicting EBITDA of $822.98M – an increase of 97.50%. Over the next seven years, experts anticipate that Halozyme Therapeutics's EBITDA will grow at a rate of 110.32%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| YPSN Stock Forecast | Ypsomed Holding | Buy |
18
|
CHF359.00 | Buy/Sell | CHF330.00 | -8.08% |
| 4183 Stock Forecast | Mitsui Chemicals | Outperform |
18
|
¥3.99k | Buy/Sell | ¥4.62k | 27.98% |
| COOP Stock Forecast | Mr. Cooper Group | Outperform |
16
|
$81.72 | Buy/Sell | $75.00 | 8.91% |
Halozyme Therapeutics EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Halozyme Therapeutics's EBIT has grown by 135.73%, from $144.26M to $340.07M. For the next year, analysts are expecting EBIT to reach $698.14M – an increase of 105.29%. Over the next seven years, experts predict that EBIT will grow by 313.15%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| PFSI Stock Forecast | PennyMac Financial Services | Outperform |
14
|
$92.07 | Buy/Sell | $85.14 | 19.47% |
| PRGO Stock Forecast | Perrigo Co PLC | Outperform |
16
|
$31.23 | Buy/Sell | $44.75 | 26.80% |
| BHC Stock Forecast | Bausch Health Companies | Hold |
15
|
$8.56 | Buy/Sell | $9.50 | 10.98% |
Halozyme Therapeutics EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Halozyme Therapeutics's EPS has fallen from $0.91 to $0.00 – a 100.00% decrease. In the next year, analysts are expecting an increase in EPS, predicting it will reach $3.79 – an increase of 100.00%. The Halozyme Therapeutics forecast is for EPS to reach $10.32 or grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| AMPH Stock Forecast | Amphastar Pharmaceuticals | Outperform |
14
|
$41.00 | Buy/Sell | $69.00 | 51.22% |
| MDRX Stock Forecast | Veradigm | Outperform |
13
|
$8.03 | Buy/Sell | $16.33 | 49.44% |
| RWT Stock Forecast | Redwood Trust | Outperform |
10
|
$5.76 | Buy/Sell | $11.28 | 36.81% |
Site Navigation
.jpg)